features of MenC conjugate vaccine

Last reviewed 01/2018

• developed using same technology used in the development of Hib vaccine
• the vaccine induces a T-cell dependent antibody response and immunological memory - it is protective in children under 2 years of age
• carrier proteins used in MenC conjugate vaccines are tetanus toxoid or variant diphtheria toxin (CRM197)
• the vaccine should be reconstituted immediately before use with the dilutent supplied by the manufacturer - once the vaccine has been reconstituted then it must be used within one hour
• administered as a intramuscular or deep subcutaneous injection - in patients with bleeding disorders or thrombocytopaenia then the vaccine may be given subcutaneously